In a 2024 clinical practice guideline issued by the Kidney Disease: Improving Global Outcomes (KDIGO) organization, a ...

In a 2024 clinical practice guideline issued by the Kidney Disease: Improving Global Outcomes (KDIGO) organization, a ...

Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization ...

Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...

Improving Global Outcomes (KDIGO) organization updated its existing clinical practice guideline in 2024 on evaluation and ...

Improving Global Outcomes organization's updates to its 2024 guidelines expand SGLT2 inhibitor use and refine chronic kidney ...

"Learn about the importance of kidney health and comprehensive screening during National Kidney Month. Discover how CarelonRx ...

Background Effective management of coexisting heart failure (HF), chronic kidney disease (CKD) and type 2 diabetes mellitus ...

Tolvaptan Slows Progression in Genetic Kidney Disease A real-world long-term analysis reveals the benefits of tolvaptan in slowing kidney function decline in autosomal dominant polycystic kidney ...

Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source ...